相关实验视频
Updated: Jun 23, 2026
14:19
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
B型尿素和喷射分数用于心肌梗塞后的预后
A Mark Richards1, M Gary Nicholls, Eric A Espiner
1Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand. mark.richards@cdhb.govt.nz
Circulation
|May 29, 2003
概括
血B型尿素 (BNP) 和左心室喷射分数 (LVEF) 是心肌梗塞后不良事件的关键预测因素. 结合BNP和LVEF提供了优越的风险分层,改善了患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 生物标志物 生物标志物
- 预测指标的预测指标
背景情况:
- 血B型尿酸 (BNP) 独立预测急性冠状动脉综合征中的死亡率,心力衰竭和心肌梗塞.
- 左心室喷射分数 (LVEF) 对于急性心脏损伤后的预后和治疗反应至关重要.
研究的目的:
- 在大量急性心肌梗塞患者中评估BNP,氨基终端BNP (N-BNP),北上腺素和放射性核酸LVEF的同时测量的预后效益.
- 为了确定组合的BNP/N-BNP和LVEF测量是否与单个标志物相比改善风险分层.
主要方法:
- 对666名急性心肌梗塞患者队列的分析.
- 同时测量血BNP,N-BNP,北上腺素和放射性核酸LVEF.
- 统计分析以评估独立的预测值和综合风险分层的有效性.
主要成果:
- 两种B型 (BNP,N-BNP) 和LVEF独立预测死亡,心力衰竭和新的心肌梗塞 (P<0.001).
- 结合的BNP/N-BNP和LVEF显著改善了风险分层,超出了单个标志物.
- 升高的N-BNP/BNP预测了新的心肌梗塞,特别是在LVEF<40%的患者中.
结论:
- 血N-BNP (或BNP) 和LVEF是对心肌梗塞后主要不良事件的互补,独立的预测因素.
- 结合N-BNP/BNP和LVEF的测量,可以大大提高风险分层.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...